907-P: Impact of Using a Digital Therapeutic and Blood Glucose Meter on Glycemic Control and Variability

ARJUN KRISHNAKUMAR; VASANTH KUMAR; BANSHI D. SABOO; VARSHA KHATRY; SHILPA JOSHI; RISHI R. ADHIKARY; SIDDDHESH KOLWANKAR; VINOD MATTOO

doi:10.2337/db20-907-P

Poster Presentations: Clinical Diabetes/Therapeutics

907-P: Impact of Using a Digital Therapeutic and Blood Glucose Meter on Glycemic Control and Variability

ARJUN KRISHNAKUMAR,
VASANTH KUMAR,
BANSHI D. SABOO,
VARSHA KHATRY,
SHILPA JOSHI,
RISHI R. ADHIKARY,
SIDDDHESH KOLWANKAR and
VINOD MATTOO

Hyderabad, India, Ahmedabad, India, Mumbai, India

Diabetes 2020 Jun; 69(Supplement 1): -. https://doi.org/10.2337/db20-907-P

Abstract

Background: High out of pocket expenses have led to poor diabetes self-management and glycemic control in India. This study evaluates the impact of an iPDM (integrated personalized diabetes management) on blood glucose (BG) control.

Methods: Study participants (n=286) used an iPDM consisting of the Accu-Chek® Active BG meter and the Wellthy Care™ digital therapeutic platform (WDTx), which allowed them to log BG values while receiving artificial intelligence-powered real-time feedback and self-management education. The BG values at baseline (M0), month 2 (M2), month 4 (M4), and month 6 (M6) were analyzed. Mean BG (MBG), Fasting BG (FBG), Post-meal BG (PBG), number of hypoglycemia logs (<70 mg/dl), and in-range logs (FBG: 70-130 mg/dl; MBG/PBG: 70-180 mg/dl) were evaluated.

Results: The average number of active days and BG logs by the participants was 75.9 days (95% CI: 66.0-85.7 days) and 73 logs (95% CI: 67-79 logs), respectively. The BG values and logs are summarized in Table 1. There was a significant reduction in BG from M0 to M2 after which the BG was stable over M4 and M6. There was also a reduction in the number of hypoglycemia logs and a corresponding increase in the number of in-range BG logs from M0 through M6.

Conclusion: This study shows that an iPDM using SMBG and WDTx can be an effective and affordable tool for improving glycemic control and reducing hypoglycemia events in resource limited countries like India.

Disclosure A. Krishnakumar: Employee; Self; Wellthy Therapeutics. V. Kumar: None. B.D. Saboo: None. V. Khatry: None. S. Joshi: Consultant; Self; Wellthy Therapeutics. R.R. Adhikary: Employee; Self; Wellthy Therapeutics. S. Kolwankar: Employee; Self; Wellthy Therapeutics. V. Mattoo: None.

http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.